CD5024 1%

· Galderma R&D

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD5024 1%, covering 2020-12-11 to 2020-12-11. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of CD5024 1% in Acne Vulgaris [Phase 2]